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Sotagliflozin is a dual inhibitor of sodium–glucose co-transporter
(SGLT) 1 and 2, although it is approximately 20-fold more selec-
tive for SGLT2.1 SGLT1 contributes to glucose reabsorption in
the gastrointestinal tract, whereas SGLT2 has this function in the
proximal renal tubule.2 The effects of sotagliflozin in heart failure
were recently studied in the Effect of Sotagliflozin on Cardiovas-
cular Events in Patients with Type 2 Diabetes Post Worsening
Heart Failure trial (SOLOIST-WHF).3 SOLOIST-WHF had a com-
plex history including withdrawal of the major sponsor, a resulting
shortfall in funding and the impact of the novel coronavirus dis-
ease pandemic. As a result, fewer patients were recruited than
originally intended (1222 instead of 4000), the trial was termi-
nated early, potential endpoints were not fully adjudicated, and the
primary outcome was changed from that originally planned (first
occurrence of either hospitalization for heart failure or cardiovas-
cular death). Despite these tribulations, the investigators are to
be congratulated in maintaining the integrity of the trial, bringing
it to successful completion, and promptly analysing and reporting
their findings. As a result, SOLOIST-WHF fills an important gap in
knowledge about the use of SGLT2 inhibitors to treat patients with
heart failure and reduced ejection fraction (HFrEF) and offers a tan-
talising suggestion that these drugs may also be beneficial in patients
with heart failure and preserved ejection fraction (HFpEF).3
Unlike the EMPagliflozin outcomE tRial in Patients With
chrOnic heaRt Failure With Reduced Ejection Fraction trial
(EMPEROR-Reduced) and the Dapagliflozin And Preven-
tion of Adverse outcomes in Heart Failure trial (DAPA-HF),
SOLOIST-WHF enrolled patients with worsening of existing
heart failure requiring intravenous diuretic therapy, usually in the
hospital setting (the proportion enrolled out of hospital has not
been reported).4,5 At randomization, participants were required
to have a B-type natriuretic peptide (BNP) level ≥150 pg/mL
(≥450 pg/mL for patients with atrial fibrillation) or N-terminal
proBNP (NT-proBNP) ≥600 pg/mL (≥1800 pg/mL for patients




















































. with atrial fibrillation).3 There was no upper left ventricular
ejection fraction (LVEF) limit, but randomization was strati-
fied according to LVEF (<50% or ≥50%). Unlike DAPA-HF and
EMPEROR-Reduced, patients were required to have a diagnosis of
type 2 diabetes.3–8 Patients were randomized when haemodynam-
ically stable, prior to hospital discharge (n = 596) or within 3 days
after discharge (n = 626). Key exclusion criteria were systolic
blood pressure <100 mmHg, estimated glomerular filtration rate
<30 mL/min/1.73 m2 and a digoxin level >1.2 ng/mL. The revised
primary endpoint was total number of hospitalizations and urgent
visits for heart failure (first and subsequent) and deaths from
cardiovascular causes.3
Not surprisingly, patients enrolled in SOLOIST-WHF differed
in several ways from those in DAPA-HF and EMPEROR-Reduced
(Table 1).3–8 They were older and more were women and the
median LVEF was higher (all in keeping with the absence of
an upper LVEF threshold for inclusion); the median estimated
glomerular filtration rate was lower (in keeping with the greater
proportion of older people and women and requirement for
all patients to have type 2 diabetes). Because all patients had
recent worsening heart failure, the proportion remaining in New
York Heart Association class III and IV was greater than in the
earlier trials and median NT-proBNP was higher than in DAPA-HF
(although not EMPEROR-Reduced, reflecting the inclusion criteria
for that trial).3–8
The findings of SOLOIST-WHF are difficult to compare directly
with DAPA-HF and EMPEROR-Reduced because of the different
patient population enrolled, characteristics of the drug and the
use of unadjudicated events. Hospitalized patients have higher
event rates than ambulatory patients and participants with type
2 diabetes higher rates than those without diabetes. The adju-
dication process usually rejects a substantial proportion of sus-
pected worsening heart failure events, so use of unadjudicated
events also inflates the endpoint rate.9 The single outcome not
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Table 1 Key baseline characteristics of patients in DAPA-HF, EMPEROR-Reduced and SOLOIST-WHF
DAPA-HF (n = 4744) EMPEROR-Reduced (n = 3730) SOLOIST-WHF (n = 1222)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age, years 66 67 69
Female sex, % 23 24 34
NYHA class III–IV, % 32 25 50
LVEF, % 31 27 35b
Prior HF hospitalisation (or equivalent), % 47 31a 100
Median NT-proBNP, pg/mL 1437 ∼1900 ∼1780
Atrial fibrillation, % 40 37 47
Diabetes (history), % 42 50 100
eGFR, mL/min/1.73 m2 66 62 50b
Beta-blocker, % 96 95 92
MRA, % 71 71 64
RAS blocker (including ARNI), % 94 89 91
ARNI, % 11 19 17
Values are means or proportions (%) unless otherwise stated.
ARNI, angiotensin receptor–neprilysin inhibitor; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist;
NT-proBNP, N-terminal pro B-type natriuretic peptide; NYHA, New York Heart Association; RAS, renin–angiotensin system.
aWithin the previous 12 months.
bMedian.
influenced by adjudication is all-cause mortality and the rate of
death from any cause in the placebo group of SOLOIST-WHF
was 16.3 per 100 person-years of follow-up, much higher than
the rates of 9.5 and 10.7 per 100 person-years in DAPA-HF and
EMPEROR-Reduced, respectively. Although not the final, revised,
primary outcome, the SOLOIST-WHF investigators did report
time to first occurrence of hospitalization for worsening heart fail-
ure or death from cardiovascular causes, which was the primary
endpoint in EMPEROR-Reduced and the first secondary endpoint
in DAPA-HF. The hazard ratio for this outcome was 0.71 [95%
confidence interval (CI) 0.56–0.89] in SOLOIST-WHF, compared
with 0.75 (0.65–0.86) in EMPEROR-Reduced and 0.75 (0.65–0.85)
in DAPA-HF.3–5,10 This one outcome that can be compared across
all three trials demonstrates remarkable consistency of benefit,
despite the differences in populations enrolled. In SOLOIST-WHF,
the hazard ratio for the revised primary endpoint, total num-
ber of hospitalizations and urgent visits for heart failure (first
and subsequent) and deaths from cardiovascular causes, was 0.67
(0.52–0.85). This was also examined post hoc in DAPA-HF, where
the rate ratio was 0.74 (0.64–0.86) [unpublished]. Breaking down
this primary composite outcome in SOLOIST-WHF into its com-
ponents, showed that sotagliflozin led to large and statistically sig-
nificant reductions in the total number of worsening heart failure
events (hazard ratio 0.64, 95% CI 0.49–0.83); in a post hoc analysis
of DAPA-HF the rate ratio for this composite was 0.70 (0.58–0.84)
[unpublished]. There was also a favourable trend to lower cardio-
vascular mortality in SOLOIST-WHF, in keeping with the benefits
observed in the earlier SGLT2 inhibitor trials. Due to the smaller
sample size and shorter follow-up (median of only 9.0 months) than
planned, SOLOIST-WHF was not powered to provide a statisti-
cally robust assessment of the effect of sotagliflozin on mortality
(there were 141 deaths in SOLOIST-WHF compared with 515


















































. results of all three trials are pooled, there is a clear reduction in
both cardiovascular and all-cause mortality (Figure 1).
The key subgroups of interest were LVEF <50% vs. ≥50% and
treatment initiation before or after discharge from hospital, each
of which showed a benefit consistent with that in the trial overall.
Clearly, the LVEF subgroup is particularly notable as it hints at
efficacy in HFpEF similar to that in HFrEF, although the number of
patients with a LVEF ≥50% was modest (n = 256). In an additional
LVEF subgroup analysis, the hazard ratio for the primary outcome
was 0.69 (0.51–0.92) in patients with a LVEF <40% (n = 725) and
0.68 (0.45–1.03) in patients with a LVEF ≥40% (n = 494).
The analysis of safety was also crucial, especially as the patients
studied were enrolled either in hospital or shortly after dis-
charge. Concerns have been raised about administration of
SGLT2 inhibitors in hospitalized patients and the risk of diabetic
ketoacidosis.11,12 Despite all patients in SOLOIST-WHF having
type 2 diabetes, in the safety analysis only 2 of 605 patients in the
sotagliflozin group experienced diabetic ketoacidosis compared
with 4 of 611 patients in the placebo group. Of interest, signifi-
cantly more patients in the sotagliflozin group (n = 42) experienced
diarrhoea than in the placebo group (n = 25), a difference not
reported in DAPA-HF or EMPEROR-Reduced and one likely to
reflect SGLT1 inhibition in the intestines.
In summary, SOLOIST-WHF contributes three very important
findings relevant to the use of SGLT2 inhibitors in clinical prac-
tice. First, it adds a third trial confirming the benefits of drugs in
this class for patients with HFrEF, creating a particularly strong evi-
dence base (Figure 1). Second, SOLOIST-WHF answers the ques-
tion about whether this treatment can be started in hospital fol-
lowing an episode of decompensation (and the answer is resound-
ingly yes). Third, SOLOIST-WHF shows that use of a SGLT2
inhibitor in patients stabilized after an episode of decompensation
is not associated with an increased risk of diabetic ketoacidosis.
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Figure 1 Meta-analysis of DAPA-HF, EMPEROR-Reduced and SOLOIST-WHF. The figure shows pooled treatment effect estimates calculated
from the reported individual trial-level estimates using a fixed-effect meta-analysis model. CI, confidence interval; HR, hazard ratio; RR, rate
ratio.
Here it is worth specifying how ‘stabilized’ was defined in the
trial: a systolic blood pressure ≥100 mmHg, no treatment with
intravenous inotropic therapy or intravenous vasodilators within
2 days prior to randomization, and no requirement for mechan-
ical ventilation or oxygen therapy in the last 24 h. Patients also
had to have discontinued intravenous diuretic and chronic oral
loop diuretic prescribed and/or administered. Patients with dia-
betes, especially those on insulin, or an insulin secretagogue, may
still be at risk of diabetic ketoacidosis if fluid and calorie intake is
curtailed, insulin dose reduced, or both.11,12 Finally, as alluded to
earlier, SOLOIST-WHF offers the first tantalising hint that SGLT2
inhibitors might also be beneficial in HFpEF, although we need
to wait until later in 2021–22 for definitive proof, which will
be provided by the two large ongoing dedicated HFpEF trials,
i.e. EMPEROR-Preserved (NCT03057951) and the Dapagliflozin
Evaluation to improve the LIVEs of patients with pReserved
ejection fraction heart failure (DELIVER, NCT03619213). Impor-
tantly, DELIVER also includes hospitalized and recently discharged
patients, as in SOLOIST-WHF. While waiting for the results of
EMPEROR-Preserved and DELIVER, the immediate priority for
physicians is to implement this highly effective (and cost-effective)
treatment in patients with HFrEF, the majority of whom are eligible
for it.13,14 SGLT2 inhibitors can now be used in both inpatients and
outpatients.
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